Comparing dose prediction software used to manage gentamicin dosing

Internal Medicine Journal

Volumn 43, Issue 5, 2013, Pages 519-525

  Wong, C ^a   Kumar, S S ^a,b   Graham, G G ^a,b   Begg, E J ^c   Chin, P K L ^c   Brett, J ^b   Ray, J E ^b   Marriott, D J E ^a,b   Williams, K M ^a,b   Day, R O ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aladdin; Creatinine; Directed therapy; Gentamicin; Pharmacokinetics; TCIWorks

Indexed keywords

GENTAMICIN;

ADULT; AGED; ARTICLE; CASE REPORT; COMPARATIVE STUDY; COMPUTER PROGRAM; CREATININE CLEARANCE; DRUG BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; SOFTWARE;

EID: 84877886428     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12067     Document Type: Article

References (13)

1. Antibiotic Expert Group. Therapeutic Guidelines: Antibiotic. Version 14. Melbourne: Therapeutic Guidelines Ltd; 2010.
2. Australian Medicines Handbook; Rossi S, ed. Autralian Medicines Handbook 2012. Adelaide: Australian Medicines Handbook Pty Ltd; 2012.
3. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-609.
4. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-135.
5. Australian Society for Antimicrobials. Aminoglycoside Levels And Daily Dose INdicator (ALADDIN). [cited 2012 Aug 27]. [Download page on the Internet]. Perth: Australian Society for Antimicrobials. Available from URL: http://www.asainc.net.au/aladdin
6. Avent ML, Teoh JL, Lees J, Eckert CA, Kirkpatrick CMJ. Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit 2011; 33: 592-601.
7. Nicolau DP, Freeman CD, Belliveau PPl, Nightingale CH, Ross JW, Quintalini R. Experience with once-daily aminoglycoside program administered to 2, 184 adult patients. Anitmicrob Agent Chemother 1995; 39: 650-655.
8. TCIWorks Development Team. TCIWorks [Homepage on the Internet]. [Cited 27 Aug 2012]. Available from URL: http://www.tciworks.info/
9. Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-645.
10. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. London: European Medicines Agency; 2010. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. [Updated 2011 Oct 28; cited 2012 Aug 27]. Available from URL: http://www.tga.gov.au/industry/%20pm-euguidelines-adopted-clinical.htm
11. Pearson GA, McLachlan AJ, Razan I. Bioequivalence: how, why and what does it really mean? J Pharm Pract Res 2004; 34: 195-200.
12. Janmahasatian S, Duffull SB, Ash S, Ward LC, Bryne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-1065.
13. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CMJ, Green B. Lean body mass normalises the effects of obesity on renal function. Br J Clin Pharmacol 2008; 65: 964-965.